| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expenses) | -118,586 | -14,223 | -251,185 | -183,864 |
| Loss before provision income tax | -1,286,996 | -2,309,206 | -944,190 | -133,917 |
| Provision for income tax expense | 527 | 23,627 | - | 355 |
| Net loss | -1,287,523 | -2,332,833 | -944,190 | -134,272 |
| Net loss attributable to noncontrolling interests | -41,010 | -75,811 | -102,115 | 52,289 |
| Net loss attributed to abvc and subsidiaries | -1,246,513 | -2,257,022 | -842,075 | -186,561 |
| Foreign currency translation adjustment | 3,236 | 39,640 | -1,493 | 25,389 |
| Comprehensive loss | -1,243,277 | -2,217,382 | -843,568 | -161,172 |
| Basic (in dollars per share) | -0.05 | -0.13 | -0.06 | -0.02 |
| Basic (in shares) | 23,256,590 | 17,386,536 | 14,968,232 | 12,405,261 |
| Diluted (in dollars per share) | -0.05 | -0.13 | -0.06 | -0.02 |
| Diluted (in shares) | 23,256,590 | 17,386,536 | 14,968,232 | 12,405,261 |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)